Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eurartesim proof-of-concept study in imported uncomplicated Plasmodium vivax malaria
NL-OMON40593Phase 2Withdrawn
- Sponsor
- Leadiant Biosciences
- Start
- Feb 2014
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dihydroartemisinin in malaria, sponsored by Leadiant Biosciences. Primary endpoint: Day 21 uncorrected adequate clinical and parasitological response. Planned start Feb 2014; status: withdrawn.
02
Drugs
dihydroartemisinin
03
Conditions
malaria
Beyond the preview
Go deeper on NL-OMON40593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40593.